15 related articles for article (PubMed ID: 9832306)
1. Vaccine development against HIV-1: current perspectives and future directions.
Edgeworth RL; San JH; Rosenzweig JA; Nguyen NL; Boyer JD; Ugen KE
Immunol Res; 2002; 25(1):53-74. PubMed ID: 11868934
[TBL] [Abstract][Full Text] [Related]
2. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids.
Delézay O; Hammache D; Fantini J; Yahi N
Biochemistry; 1996 Dec; 35(49):15663-71. PubMed ID: 8961929
[TBL] [Abstract][Full Text] [Related]
3. SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms.
Yahi N; Fantini J; Baghdiguian S; Mabrouk K; Tamalet C; Rochat H; Van Rietschoten J; Sabatier JM
Proc Natl Acad Sci U S A; 1995 May; 92(11):4867-71. PubMed ID: 7761414
[TBL] [Abstract][Full Text] [Related]
4. SPC3, an anti-HIV peptide construct derived from the viral envelope, binds and enters HIV target cells.
Barbouche R; Miquelis R; Sabatier JM; Fenouillet E
J Pept Sci; 1998 Dec; 4(8):479-85. PubMed ID: 9927254
[TBL] [Abstract][Full Text] [Related]
5. V3 loop-derived peptide SPC3 inhibits infection of CD4- and galactosylceramide- cells by LAV-2/B.
Moulard M; Mabrouk K; Martin I; Van Rietschoten J; Rochat H; Sabatier JM
J Pept Res; 1999 Jun; 53(6):647-55. PubMed ID: 10408339
[TBL] [Abstract][Full Text] [Related]
6. Correlation of antiviral activity with beta-turn types for V3 synthetic multibranched peptides from HIV-1 gp120.
Mabrouk K; Van Rietschoten J; Rochat H; Loret EP
Biochemistry; 1995 Jul; 34(26):8294-8. PubMed ID: 7599121
[TBL] [Abstract][Full Text] [Related]
7. Properties of HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials.
Barbouche R; Fenouillet E; Papandréou MJ; Kiény MP; Sabatier JM
J Pept Res; 1998 Oct; 52(4):283-8. PubMed ID: 9832306
[TBL] [Abstract][Full Text] [Related]
8.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
